Recro Pharma Inc. (REPH)
NASDAQ: REPH
· Real-Time Price · USD
2.09
-0.01 (-0.48%)
At close: Mar 22, 2022, 5:00 AM
Recro Pharma Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 27.72M | 23.59M | 21.8M | 21.53M | 24.28M | 21.59M | 23.15M | 21.19M | 22.3M | 18.24M | 18.02M | 16.8M |
Cost of Revenue | 20.02M | 19.87M | 17.33M | 19.28M | 17.44M | 16.05M | 17.47M | 16.11M | 15.71M | 13.16M | 12.33M | 14.34M |
Gross Profit | 7.7M | 3.72M | 4.47M | 2.25M | 6.84M | 5.53M | 5.68M | 5.08M | 6.6M | 5.08M | 5.68M | 2.47M |
Operating Income | 5.91M | -1.76M | -968K | -6.76M | -32.5M | 215K | 302K | -851K | 1.1M | 336K | 1.84M | -2.86M |
Interest Income | 75K | 79K | 109K | 131K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -768K | -4.59M | -3.17M | -4.61M | -8.06M | -3.33M | -3.12M | -4.26M | -2.36M | -3.49M | 1.23M | -6.76M |
Net Income | -786K | -4.59M | -3.21M | -4.68M | -9.17M | -6.87M | -6.54M | -7.68M | -5.81M | -3.49M | 1.23M | -6.76M |
Selling & General & Admin | 5.78M | 5.31M | 5.27M | 4.66M | 6.01M | 5.08M | 5.16M | 5.71M | 5.3M | 4.61M | 3.79M | 4.68M |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | 167K | 168K | 168K | 184K | 67.3M | 244K | 220K | 221K | 202K | 135K | 54K | 646K |
Operating Expenses | 5.95M | 5.48M | 5.44M | 4.85M | 73.31M | 5.32M | 5.38M | 5.93M | 5.5M | 4.74M | 3.84M | 5.33M |
Interest Expense | -2.59M | -2.91M | -2.31M | -2.15M | -24.44M | 3.54M | 3.42M | 3.41M | 3.45M | 3.82M | 3.96M | 3.9M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 25.97M | 25.35M | 22.77M | 24.13M | 90.74M | 21.37M | 22.85M | 22.05M | 21.21M | 17.9M | 16.18M | 19.67M |
Income Tax Expense | 18K | 3K | 39K | 72K | 1.1M | 3.54M | 3.42M | 3.41M | 3.45M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 95.23M | 100.64M | 87.33M | 84.8M | 57.88M | 56.67M | 56.6M | 56.35M | 51.42M | 51.42M | 39.02M | 29.74M |
Shares Outstanding (Diluted) | 95.23M | 100.64M | 87.33M | 84.8M | 57.88M | 56.67M | 56.6M | 56.35M | 51.42M | 51.42M | 39.35M | 29.74M |
EPS (Basic) | -0.01 | -0.05 | -0.04 | -0.06 | -0.16 | -0.12 | -0.12 | -0.14 | -0.11 | -0.07 | 0.03 | -0.23 |
EPS (Diluted) | -0.01 | -0.05 | -0.04 | -0.06 | -0.16 | -0.12 | -0.12 | -0.14 | -0.11 | -0.07 | 0.03 | -0.23 |
EBITDA | -7.52M | -1.76M | -968K | -2.6M | -38.7M | 2.38M | 2.32M | -851K | 3.03M | 2.24M | 6.84M | -781K |
EBIT | -3.36M | -7.5M | -5.49M | -6.76M | -32.5M | 215K | 302K | n/a | 1.1M | 336K | 5.19M | -2.86M |
Depreciation & Amortization | 4.7M | -39.59K | 122.08K | 4.16M | -6.2M | 2.17M | 2.02M | 2.01M | 1.93M | 1.91M | 1.65M | 2.08M |